Related Experiment Video

Updated: Jul 7, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

[Congestive heart failure is a common disease with complex inheritance--new perspectives through genome wide

P Linsel-Nitschke1, H Schunkert, J Erdmann

  • 1Medizinische Klinik II, Universität zu Lübeck, Ratzeburger Allee 160, 23538, Lübeck, Germany.

Der Internist
|February 28, 2008
PubMed

Insights

Congestive heart failure (CHF) genetics primarily studied rare forms. This review explores common genetic risk factors for complex CHF using genome-wide association studies.

Area of Science:

  • Cardiovascular Medicine
  • Human Genetics
  • Genomics

Context:

  • Congestive heart failure (CHF) is a complex syndrome, often the end stage of various cardiovascular disorders.
  • Previous genetic research on CHF predominantly focused on rare familial forms, such as hypertrophic or dilated cardiomyopathy.
  • These rare forms are typically caused by single gene mutations with Mendelian inheritance patterns.

Purpose:

  • To shift focus from rare familial CHF to the genetic underpinnings of common, complex CHF.
  • To review the impact of advanced technologies, specifically genome-wide association studies (GWAS), in identifying common genetic risk factors for CHF.
  • To provide an overview of current understanding and future directions in the complex genetics of congestive heart failure.

Summary:

  • This review highlights that while rare familial cardiomyopathies have been extensively studied genetically, they represent a small fraction of overall congestive heart failure (CHF) cases.
  • The majority of CHF cases exhibit complex inheritance patterns, indicating the involvement of multiple genes and environmental factors.
  • Genome-wide association studies (GWAS) are emerging as a powerful tool to uncover common genetic variants associated with the complex trait of CHF.

Impact:

  • Advances understanding of the genetic architecture of congestive heart failure beyond rare Mendelian forms.
  • Facilitates the identification of novel therapeutic targets and personalized risk prediction strategies for the broader CHF population.
  • Emphasizes the utility of large-scale genomic approaches like GWAS in dissecting complex diseases.

More Related Videos

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound (30/45MHZ) System07:34

Fetal Mouse Cardiovascular Imaging Using a High-frequency Ultrasound (30/45MHZ) System

Published on: May 5, 2018

Related Concept Videos

Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...